CONMED Corporation Form 10-Q Summary
Business Context and Reporting Period
CONMED is a medical technology company focused on surgical devices and equipment for minimally invasive procedures, including arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring, endosurgery and endoscopic technologies. This unaudited report covers the three months ended March 31, 2012, compared with the three months ended March 31, 2011.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2012 | Change |
|---|---|---|---|
| Net sales | $183.5 million | $194.3 million | 5.9% increase |
| Gross profit | $95.7 million | $100.9 million | 5.4% increase |
| Gross margin | 52.2% | 51.9% | Down 0.3 points |
| Income from operations | $17.3 million | $17.0 million | 1.4% decrease |
| Operating margin | 9.4% | 8.7% | Down 0.7 points |
| Net income | $9.0 million | $10.0 million | 10.8% increase |
| Diluted EPS | $0.31 | $0.35 | Increase of $0.04 |
| Net cash from operations | $20.7 million | $7.6 million | Decrease of $13.1 million |
Interest expense declined to $1.4 million from $1.8 million, while the prior-year period included $1.1 million of debt discount amortization. The effective tax rate declined to 36.0% from 37.4%, primarily because of higher earnings in lower-tax foreign jurisdictions.
At March 31, 2012, cash and cash equivalents were $19.5 million. Total current assets were $351.3 million and net working capital was $185.4 million. Current and long-term debt totaled approximately $193.2 million, including $53.2 million outstanding under the term loan, $130.0 million under the revolving facility and $9.6 million under a mortgage note. Revolving-facility availability was $110.6 million, with approximately $9.4 million reserved for letters of credit.
Material Changes Versus the Prior Comparable Period
- Sales growth was led by Arthroscopy, which increased 14.3% to $86.2 million, including the impact of the MTF distribution agreement. Endoscopic Technologies increased 7.6%, Powered Surgical Instruments increased 1.3%, and Endosurgery increased 1.7%.
- Electrosurgery sales declined 4.7% to $22.5 million, and Patient Care sales declined 3.6% to $16.0 million.
- Single-use product sales increased 9.0% to $154.3 million, while capital equipment sales declined 4.5% to $40.0 million. Management attributed weaker capital sales to hospital purchasing constraints.
- Operating income declined despite higher sales. The combined Linvatec, Electrosurgery and Endosurgery segment margin fell to 12.7% from 15.7%, reflecting administrative consolidation costs, Nordic distributor acquisition costs and legal arbitration costs.
- Research and development expense declined to $7.1 million from $7.7 million, primarily due to lower spending on the ECOM project.
- Operating cash flow fell because of a $6.5 million pension contribution, higher accounts receivable associated with the MTF agreement and higher incentive compensation payments.
- Investing cash outflow increased to $70.5 million, primarily because of the $64.1 million payment related to the MTF joint development and distribution agreement, compared with $4.2 million in the prior year.
- The company adopted a $0.15-per-share quarterly dividend. The first dividend was paid on April 5, 2012, and $4.3 million was recorded as payable at quarter-end.
Guidance, Outlook, Risks and Unusual Items
- The MTF agreement required an upfront payment of $63.0 million and provides for up to $84.0 million of contingent payments over four years, including $34.0 million due within the next fiscal year. The company believes the supply targets are probable and accrued the full $84.0 million.
- Management expects 2012 capital expenditures of approximately $20.0 million and restructuring costs of approximately $4.0 million to $5.0 million. First-quarter restructuring costs totaled $1.5 million in cost of sales and $0.3 million in other expense.
- Management expects to contribute an additional $2.7 million to the pension plan during the remainder of 2012 and the first quarter of 2013, after contributing $6.5 million in the first quarter related to the 2011 plan year.
- The company expects to use its revolving facility to fund $53.2 million of scheduled term-loan principal payments due June 30 and September 30, 2012. It was in compliance with its debt covenants at March 31, 2012.
- Other expense increased to $2.0 million from $0.7 million, including $1.0 million of legal costs related to arbitration with a former distributor and $0.7 million related to the acquisition of a Nordic distributor. Management expected a decision on the arbitration matter on May 9, 2012 and had not accrued additional amounts because it believes the claim is without merit.
- Key risks include hospital capital-spending constraints, economic conditions in Europe and other international markets, foreign-exchange volatility, regulatory and quality actions, product liability, litigation, competition, technology changes, availability of allograft tissue and the ability to realize expected benefits from acquisitions and restructuring.
- The company maintains $25 million of product-liability insurance per incident and in the annual aggregate, but warns that future claims could exceed coverage. Management does not expect pending claims or investigations to have a material adverse effect, although no assurance is provided.
Important Facts for Investors to Verify
- Whether the MTF agreement produces the expected revenue and cash flow and whether all $84.0 million of contingent payments becomes payable.
- Progress toward scheduled debt repayments, revolving-facility capacity and compliance with credit-agreement covenants.
- Whether capital-equipment demand improves and whether strong single-use growth continues.
- Actual restructuring costs and savings compared with the $4.0 million to $5.0 million 2012 estimate.
- Resolution and potential financial exposure from the former-distributor arbitration.
- Whether lower operating margins, Patient Care losses and accumulated goodwill and intangible assets create future impairment risk.
- Cash flow conversion, particularly the effect of pension contributions, working-capital requirements and dividend payments.